曲美替尼联合全脑放疗治疗脑转移瘤的I期研究
这项单中心、前瞻性、3+3设计的I期试验评估曲美替尼联合同步全脑放疗(37.5 Gy/15次)治疗脑转移瘤的最大耐受剂量。10例患者入组,剂量水平1-3分别为1.0、1.5、2.0 mg;剂量限制性毒性在剂量水平2达到(4级血小板减少和3级腹泻各1例),最大耐受剂量小于1.5 mg。由于实践模式转向立体定向放射外科,试验提前终止。
要点
- 曲美替尼同步全脑放疗在剂量水平2达到剂量限制性毒性(4级血小板减少和3级腹泻各1例)。
- 最大耐受剂量小于1.5 mg,13例次3-4级毒性中12例次发生在剂量水平2(6例中4例)。
- 中位总生存期为2.2个月,未观察到5级毒性。
核心结论
- 在代表现代全脑放疗候选人群的患者中,曲美替尼联合全脑放疗毒性高,最大耐受剂量小于1.5 mg。
- 曲美替尼联合立体定向放射外科的安全性仍是未来研究的重要问题。
研究设计与样本
- 单中心、前瞻性、3+3设计的I期临床试验,旨在确定曲美替尼联合全脑放疗的最大耐受剂量。
- 入组10例脑转移瘤患者(中位年龄59岁[范围47-64],中位脑转移灶数目5个[范围1-10],50%为黑色素瘤)。
- 患者每日接受曲美替尼共28天,从全脑放疗(37.5 Gy/15次)前7天开始并持续至放疗期间;剂量水平1-3分别为1.0、1.5、2.0 mg。
- 主要终点为曲美替尼联合全脑放疗的最大耐受剂量,即6例患者中≤1例发生剂量限制性毒性的最高剂量。
主要发现
- 3例和7例患者分别分配至剂量水平1和剂量水平2;1例剂量水平2患者退出。
- 其余患者中89%按方案完成治疗,但1例剂量水平2患者因全身进展在30 Gy时终止治疗。
- 观察到13例次3-4级毒性,其中12例次发生在剂量水平2(6例中4例)。
- 剂量限制性毒性在剂量水平2达到(4级血小板减少和3级腹泻各1例)。
- 未观察到5级毒性;中位总生存期为2.2个月。
关键数值与推荐
- 最大耐受剂量定义为6例患者中≤1例发生剂量限制性毒性的最高剂量。
- 剂量水平1-3分别为曲美替尼1.0、1.5、2.0 mg每日一次。
- 全脑放疗剂量为37.5 Gy/15次。
- 剂量限制性毒性在剂量水平2达到(4级血小板减少和3级腹泻各1例),最大耐受剂量小于1.5 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究期间实践模式转向立体定向放射外科,试验在完成前提前终止。
- 1例剂量水平2患者退出,1例剂量水平2患者因全身进展在30 Gy时终止治疗。
- 曲美替尼联合立体定向放射外科的安全性仍是未来研究的重要问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Trametinib is a MEK inhibitor with intracranial activity indicated for BRAF-mutant metastatic malignancies. Yet, the safety of trametinib concurrent with whole brain radiation therapy (WBRT) is unknown. We performed a single-institution, prospective, 3 + 3, phase I clinical trial to determine the maximum tolerated dose (MTD) of trametinib with WBRT. METHODS AND MATERIALS: Patients with brain metastases (BM) received daily trametinib for 28 days, starting 7 days prior to and continuing through WBRT (37.5 Gy/15 fractions). Dose levels (DL)1-3 were 1.0, 1.5, and 2.0 mg. The MTD of trametinib plus WBRT, the max dose where ≤1 of 6 patients experienced a dose limiting toxicity (DLT), was the primary endpoint. RESULTS: 10 patients were enrolled (median age-59 [47-64], BM-5 [1-10], 50% melanoma). Three and 7 patients were assigned to DL1 and 2. One DL2 patient withdrew. 89% of remaining patients completed therapy per protocol, but 1 DL2 patient with systemic progression discontinued therapy at 30 Gy. Thirteen grade (G)3-4 toxicities were observed, of which 12 occurred at DL2 (4/6 of patients). DLT was reached at DL2 (G4 thrombocytopenia and G3 diarrhea, 1 each). There were no G5 toxicities. Median overall survival was 2.2 months. During the study period, changing practice patterns favored utilization of stereotactic radiosurgery (SRS). Thus, the trial closed early prior to completion. CONCLUSIONS: In a patient population representative of modern candidates for WBRT, trametinib plus WBRT is highly toxic with a MTD <1.5 mg. The safety of trametinib with SRS remains an important question for future study.
引用
- Palmer JD, Prasad RN, Fabian D, et al. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022. PMID: 35367525. doi:10.1016/j.radonc.2022.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。